Let urosphere+ establish the preclinical proof of concept for your drug candidates.
your partner in preclinical research
Let urosphere+ establish the preclinical proof of concept for your drug candidates.
A new era is beginning for UROSPHERE.
We extend our activities to GASTROENTEROLOGY and ONCOLOGY.
Urosphere is a leading Contract Research Organization specializing in preclinical urogenital, gastro-intestinal and oncological pharmacology assays. We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo models and in vitro assays on human and animal tissues.
News // News & Events // May 23 2018
Voir le communiqué de presse
Read moreEvents // News // News & Events // Oct 31 2017
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Read moreEvents // News // News & Events // Oct 31 2017
Urosphere / Urolead is proud to be part of the Repositive PDX comsortium.
Read moreEvents // News // News & Events // Oct 31 2017
Urosphere is pleased to announce its acquisition of Urolead company.
Read moreEvents // News // News & Events // Sep 09 2017
Urosphere will present an oral communication at ICS (Florence, 12-15 september 2017)
Read moreOncology // Publications // Oct 31 2017
Effects of litoxetine on urethral pressure and detrusor overactivity in anesthetized female rats. Murielle Méen, Marc Guérard, Stefano Palea, Xavier Gamé, Philippe Lluel 32nd Annual...
Read morePublications // Urology // Oct 31 2017
Effects of litoxetine on acetic acid-induced detrusor overactivity and striated anal sphincter functions in rabbits: comparison with duloxetine. Fernando Pérez-Martinez, Philippe...
Read morePublications // Oct 31 2017
Effect of OBE022, an Oral and Selective Non-Prostanoid PGF2α Receptor Antagonist in Combination with Nifedipine for Preterm Labor: A Study on RU486-Induced Pregnant Mice. Oliver Pohl,...
Publications // Urology // Oct 31 2017
Treatment with WS® 1541 leads to a reduction of gene expression for proinflammatory mediators and growth factors in the prostate of rats with sulipride-induced BPH. Kraft S, Nöldner...
Publications // Urology // Oct 31 2017
Cultures d’organoïdes de vessie humaine : un nouveau modèle d’étude. Tostivint V, Vergnolle N, Ferrand A, Lluel P, Gamé X, Chabot S, Rouget C, Beauval JB Prog Urol. 2016 Nov;26(13):765-766.